Amicus to acquire Scioderm

Amicus Therapeutics Inc. (NASDAQ:FOLD) will acquire Scioderm LLC (Raleigh, N.C.), giving it Zorblisa ( SD-101), an undisclosed topical cream to treat epidermolysis bullosa (EB). The company expects data in 1H16 from the Phase III SD-005 trial of the compound, and hopes to begin a rolling NDA submission in 4Q15.

Scioderm shareholders will receive $229 million up front in cash and stock and are eligible for $618 million in milestones. ...